Abiomed Appoints Dr. Daniel Raess as Company Medical Advisor; Experienced Cardiovascular Surgeon Strengthens Clinical Expertise Offerings to Customers

Dr. Raess joins Abiomed from the Cardiac and Vascular SurgeryAssociates (CVSA) Group, a private medical practice specializing incardiothoracic surgery with St. Francis Hospital and The Indiana HeartHospital, both in Indianapolis. During his 20-year tenure at CVSA, andmore than 10 years using Ventricular Assist Devices (VADs), Dr. Raessworked extensively with Abiomed technology, having supported more than50 patients on Abiomed's BVS(R) 5000 Biventricular Support System andthe AB5000(TM) Circulatory Support System. He has shown very highrecovery rates (87%) utilizing the AB5000 technology, having recoveredthe native heart function for seven out of eight patients with suchillnesses as viral myocarditis and acute myocardial infarction (AMI orheart attack).

"Dr. Raess brings strong medical expertise and credibility, aswell as excellent customer knowledge to help Abiomed establish heartrecovery as the standard of care for acute events," said Michael R.Minogue, Chairman, CEO and President of Abiomed. "He will play a keyleadership role in providing our global customers with clinicaleducation, recovery protocols and administrative guidelines. We arevery excited to have him on the team."

"The use of ventricular assist devices to recover the native heartfunction has made great strides recently, especially the addition ofthe AB5000 to Abiomed's product portfolio. We're seeing that hospitalswith established protocols for cardiogenic shock have improvedoutcomes for patients. These standing orders affect thetiming-to-implant, patient management and timing-to-explant so thatpatients in acute heart failure who may recover their hearts are givenample opportunity to do so," said Dr. Raess. "I am excited to be apart of this Company and be able to share the experience I have gainedto help save more patients."

Dr. Raess received his M.D. degree from the Ohio Sate UniversityCollege of Medicine and completed his residency at Indiana UniversitySchool of Medicine, where he was also an Assistant Professor ofSurgery in the Division of Cardiothoracic Surgery. Dr. Raess holds thedistinction of being a Fellow of the American College of Surgeons, anda Fellow of the American College of Cardiology.

Dr. Raess has consulted for the company over the years beginningwith the initial clinical trials for the BVS 5000 in 1989, which waspublished in the peer-reviewed journal the Annals of Thoracic Surgery.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leadingdeveloper, manufacturer and marketer of medical products designed toassist or replace the pumping function of the failing heart. Abiomedcurrently manufactures and sells the AB5000(TM) Circulatory SupportSystem and the BVS(R) 5000 Biventricular Support System for thetemporary support of all patients with failing but potentiallyrecoverable hearts. In Europe, Abiomed offers the IMPELLA(R)RECOVER(R) minimally invasive cardiovascular support systems under CEMark approval. The IMPELLA(R) 2.5 is an investigational device limitedby Federal Law solely to investigational use in the United States.Other IMPELLA devices are not yet available for sale in the UnitedStates. The Company's AbioCor(R) Implantable Replacement Heart was thesubject of an initial clinical trial under an Investigational DeviceExemption from the United States Food and Drug Administration. TheAbioCor has not been approved for commercial distribution, and is notavailable for use or sale outside of the initial clinical trial. Foradditional information please visit: www.Abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, includingstatements regarding development of Abiomed's existing and newproducts, the Company's progress toward commercial growth, and futureopportunities. The Company's actual results may differ materially fromthose anticipated in these forward-looking statements based upon anumber of factors, including uncertainties associated withdevelopment, testing and related regulatory approvals, anticipatedfuture losses, complex manufacturing, high quality requirements,dependence on limited sources of supply, competition, technologicalchange, government regulation, future capital needs and uncertainty ofadditional financing and other risks and challenges detailed in theCompany's filings with the Securities and Exchange Commission,including the Annual Report filed on Form 10-K. Readers are cautionednot to place undue reliance on any forward-looking statements, whichspeak only as of the date of this Release. The Company undertakes noobligation to publicly release the results of any revisions to theseforward-looking statements that may be made to reflect events orcircumstances that occur after the date of this Release or to reflectthe occurrence of unanticipated events.